- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00291798
Neoadjuvant Endocrinotherapy of Breast Cancer (Mamma Carcinoma) With Exemestane
September 18, 2006 updated by: Austrian Breast & Colorectal Cancer Study Group
Neoadjuvant Endocrinotherapy of Mamma Carcinoma With Exemestane
The objective of the present clinical investigation is to determine whether hormonal therapy given preoperatively is able to reduce tumor size to an extent that facilitates breast-conserving procedures.
Study Overview
Detailed Description
This open, prospective multicenter Phase II pilot trial investigates the efficacy of exemestane, 25 mg once daily over 4 months, in postmenopausal women with primary breast cancer, measured in terms of clinical response
Study Type
Interventional
Enrollment
98
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Salzburg, Austria, 5020
- Paracelsus Medical University Salzburg, Oncology
-
Vienna, Austria, 1090
- Medical University of Vienna, General Hospital
-
Vienna, Austria, 1140
- Hanusch Hospital
-
-
Burgenland
-
Guessing, Burgenland, Austria, 7540
- Hospital of Guessing
-
-
Carinthia
-
Klagenfurt, Carinthia, Austria, 9026
- State Hospital Klagenfurt, Surgery
-
Wolfsberg, Carinthia, Austria, 9400
- State Hospital Wolfsberg
-
-
Lower Austria
-
Wiener Neustadt, Lower Austria, Austria, 2700
- Hospital of Wiener Neustadt
-
-
Styria
-
Graz, Styria, Austria, 8036
- Medical University of Graz, Oncology
-
Graz, Styria, Austria, 8036
- Gynaegological Medical University of Graz
-
-
Upper Austria
-
Linz, Upper Austria, Austria, 4020
- General Hospital Linz
-
Linz, Upper Austria, Austria, 4010
- Hospital BHS Linz
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
59 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Histologically verified breast cancer (punch biopsy), established HER-2/neu status
- Postmenopausal patients (> 1 year following outset of menopause and/or postmenopausal hormonal profile)
- Clinical staging: T2 (> 3 cm), T3, T4a-c, N0-1
- Hormone receptor positivity, i.e. estrogen and/or progesterone receptor > 10 fmol/mg cytosolic protein or ER-ICA-positive and/or PgR-ICA-positive. Positivity of + (low-grade) in one hormone receptor is only eligible in the presence of positivity in the other hormone receptor.
- no internal contraindication
- life expectation > 6 month
- written informed consent
Exclusion Criteria:
- premenopausal patients and patients with no clearly indicated menopausal status
- manifest second malignant tumor (except basalioma or in situ carcinoma of cervix uteri)
- uncontrolled internal disease i.e. diabetes mellitus, cardiac disease (NYHA III/IV)
- thromboembolic disease
- inflammatory mamma carcinoma
- existence of distant metastases
- former or simultaneously therapy with antioestrogens, aromatase inhibitors, cytostatics or radiotherapy
- corticosteroids before and during the study (except inhalant application)
- lack of compliance
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: SINGLE_GROUP
- Masking: NONE
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
rate of remission
|
Secondary Outcome Measures
Outcome Measure |
---|
Toxicity (WHO-grading)
|
rate of mastectomy
|
response of tumor subject to HER2-status
|
collection of disease free survival and overall survival
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Study Chair: Brigitte Mlineritsch, MD, Austrian Breast & Colorectal Cancer Study Group
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2000
Study Completion
March 1, 2009
Study Registration Dates
First Submitted
February 14, 2006
First Submitted That Met QC Criteria
February 14, 2006
First Posted (ESTIMATE)
February 15, 2006
Study Record Updates
Last Update Posted (ESTIMATE)
September 19, 2006
Last Update Submitted That Met QC Criteria
September 18, 2006
Last Verified
February 1, 2006
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ABCSG-17
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer
-
Baylor Breast Care CenterRecruitingBreast Cancer | Breast Neoplasm | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | HER2-positive Breast Cancer | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage III | Estrogen Receptor-positive Breast Cancer | Hormone Receptor-positive Breast Cancer | Breast Cancer InvasiveUnited States
-
Innocrin PharmaceuticalCompletedBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Male Breast Cancer | ER+ Breast Cancer | Cancer of the BreastUnited States
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast...United States
Clinical Trials on rate of remission
-
Institut Paoli-CalmettesCompletedSuperficial Colorectal TumorsFrance
-
Chinese University of Hong KongCompleted
-
Wyeth is now a wholly owned subsidiary of PfizerCompleted
-
IWK Health CentreThe Hospital for Sick Children; Alberta Children's Hospital; Stollery Children...TerminatedPediatric Ulcerative Colitis | Pediatric Crohn's Disease
-
Norwegian University of Science and TechnologyCompleted
-
Albany Medical CollegeRecruiting
-
University of VermontCompletedDiastolic Heart Failure | Diastolic Dysfunction | PacemakerUnited States
-
Shengjing HospitalCompleted
-
University of PittsburghCompletedMyositis | Dermatomyositis | PolymyositisUnited States